Zacks Investment Research upgraded shares of NOVOZYMES A/S/S (OTCMKTS:NVZMY) from a hold rating to a buy rating in a research report report published on Friday, Zacks.com reports. The brokerage currently has $54.00 price objective on the biotechnology company’s stock.

According to Zacks, “Novozymes A/S is primarily engaged in the development, production, and distribution of enzymes. Its business consists of two segments, enzyme business and bio business. The Company’s enzyme business segment offers detergent enzymes that are used in laundry and dishwashing, technical enzymes used in the transformation of starch into different kinds of sugars and have application in leather, textile, and forest product industries, food enzymes used in production of bread, wine, juice, beer, noodles, alcohol, and pasta and feed enzymes used in animal feed. Its bio business segment offers microorganisms that are used in industrial and municipal wastewater treatment, as well as in the cleaning of surfaces such as carpet, concrete, drain lines, and septic tanks in industrial and household applications. It also has application in the Biopharmaceutical ingredients used in pharmaceutical industry. Novozymes A/S is headquartered in Bagsvaerd, Denmark. “

A number of other research firms have also recently commented on NVZMY. JPMorgan Chase & Co. cut shares of NOVOZYMES A/S/S from a neutral rating to an underweight rating in a research note on Thursday, December 20th. Goldman Sachs Group raised shares of NOVOZYMES A/S/S from a sell rating to a neutral rating in a research note on Monday, January 28th. Berenberg Bank raised shares of NOVOZYMES A/S/S from a hold rating to a buy rating in a research note on Tuesday, February 5th. Finally, Bank of America initiated coverage on shares of NOVOZYMES A/S/S in a research note on Tuesday, February 12th. They issued a buy rating for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $54.00.

NOVOZYMES A/S/S stock opened at $47.49 on Friday. The company has a market cap of $14.10 billion, a P/E ratio of 27.14, a PEG ratio of 2.28 and a beta of 0.84. NOVOZYMES A/S/S has a 1-year low of $40.38 and a 1-year high of $55.84.

NOVOZYMES A/S/S (OTCMKTS:NVZMY) last posted its earnings results on Thursday, January 24th. The biotechnology company reported $0.44 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.42 by $0.02. The business had revenue of $567.89 million for the quarter. NOVOZYMES A/S/S had a net margin of 22.14% and a return on equity of 29.64%. On average, analysts forecast that NOVOZYMES A/S/S will post 1.8 earnings per share for the current fiscal year.

The business also recently declared an annual dividend, which was paid on Tuesday, March 19th. Shareholders of record on Friday, March 1st were paid a $0.504 dividend. The ex-dividend date was Thursday, February 28th. This represents a yield of 1.16%. NOVOZYMES A/S/S’s dividend payout ratio is presently 28.57%.

NOVOZYMES A/S/S Company Profile

Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. The company offers agriculture solutions, including crop protection, and animal health and nutrition solutions; fermentation, lignecellulosic hydrolysis, liquefaction, process enhancement, and saccharifaction solutions for bioenergy; baking, beverages, dairy, and protein ingredients for the food and beverage industry; and laundry, dishwashing, hand washing, and cleaning solutions for the household care industry.

Further Reading: What is a Lock-Up Period?

Get a free copy of the Zacks research report on NOVOZYMES A/S/S (NVZMY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NOVOZYMES A/S/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NOVOZYMES A/S/S and related companies with MarketBeat.com's FREE daily email newsletter.